Drug Detail
Information about PF-052112384 + PD-0325901 OR PF-052112384 + Irinotecan
Generic Name |
||
|---|---|---|
IND |
PF-052112384 + PD-0325901 OR PF-052112384 + Irinotecan | |
Brand Name (US) |
||
Manufacturer |
Pfizer | |
Drug Type |
Kinase inhibitor | |
Delivery |
Intravenous + Oral | |
Approval Status |
||
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block related tumor signal paths | |
Drug Category |
PI3K/mTOR inhibitor + MEK inhibitor + TOPO-1 inhibitor | |
Links |
|
Trials of this drug |
|
|
Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer |
Trial results |
|
Search for this drug/combination in: